The pilot study sponsored by Dana-Farber Cancer Institute aimed to evaluate the safety and feasibility of deferoxamine in patients with myelodysplastic syndromes or acute leukemia undergoing stem cell transplantation. The study was terminated due to slow patient accrual, indicating potential challenges in recruitment for future studies. The market for iron chelation therapy is significant, particularly in hematological malignancies, but the competitive landscape includes established therapies and emerging novel agents. The limited patient enrollment raises concerns about the viability of further development without robust data supporting efficacy and safety.